August 20, 2024 03:32 PM EDT

Semaglutide may come with a higher risk of suicidal thoughts, JAMA study finds

Max Bayer

Pharma Reporter

A new observational study has found an increased risk of suicidal ideation among patients who take Novo Nordisk’s flagship weight loss drug semaglutide compared to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Semaglutide may come with a higher risk of suicidal thoughts, JAMA study finds

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Moderna plans $1.1B in R&D and program cuts, delays break-even point to 2028

Sanofi buys into radiopharmaceutical field with $110M upfront, going after space held by Novartis

A new startup wants to fight cancer with 'off-the-shelf' gene therapy, securing $26M seed round

Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs

J&J expands Tremfya into IBD with new FDA approval

Aura's infrared light-activated drug stops tumor growth and preserves vision in eight eye cancer patients

Semaglu­tide may come with a high­er risk of sui­ci­dal thoughts, JA­MA study finds

Pharma Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Semaglutide may come with a higher risk of suicidal thoughts, JAMA study finds